Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

As the industry awaits official word from the administration on how the tariffs will hit, analysts go over the possibilities ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

The National Security Commission on Emerging Biotechnology recommends at least a $15 billion investment into biotech over the ...

Analysts suggested that the tariffs will have little effect on reshoring manufacturing and will likely decrease patient drug ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...

Billions in market cap are being shed as the markets reel over President Donald Trump’s escalating trade war. Eli Lilly’s ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as ...

The company is dropping its former lead molecule in favor of another antibody, RLYB116, which is being developed for a ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.